A trial investigating Regen Biopharma T cell immunotherapy for the treatment of cancer

Trial Profile

A trial investigating Regen Biopharma T cell immunotherapy for the treatment of cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs T cell vaccine-Regen Biopharma (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Apr 2016 New trial record
    • 23 Mar 2016 According to a Regen BioPharma media release, the Investigational New Drug (IND) application for this drug has been submitted to the U.S. Food and Drug Administration (FDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top